Pharmacotherapy response and diagnostic validity in atypical depression

Area of Science:

• Psychiatry and Clinical Psychology
• Pharmacological Research

Background:

• Investigated diagnostic criteria and treatment efficacy for atypical depression.
• Utilized data from the NIMH Treatment of Depression Collaborative Research Program.

Purpose of the Study:

• To assess the validity of diagnostic criteria for atypical depression.
• To determine the efficacy of tricyclic antidepressant pharmacotherapy for atypical depression.

Main Methods:

• Conducted a 16-week clinical trial with 239 outpatients diagnosed with major depressive disorder.
• Randomly assigned participants to interpersonal psychotherapy, cognitive behavior therapy, imipramine, or placebo with clinical management.
• Utilized SADS and ISI for rating atypical features and HRSD and GAS for measuring clinical outcome.

Main Results:

• Atypical features (mood reactivity, reversed vegetative symptoms) predicted non-responsiveness to imipramine compared to placebo in 25.2% of patients.
• Additional atypical features did not further differentiate the imipramine non-responsive subgroup.
• Imipramine demonstrated significant effectiveness over placebo for non-atypical depressed patients.

Conclusions:

• Atypical depression features, specifically mood reactivity and reversed vegetative symptoms, hold predictive validity for treatment outcomes.
• Findings support the inclusion of these specific atypical depressive features in diagnostic manuals like DSM-IV.
• Depression severity did not account for the predictive influence of atypical features on treatment response.